Raised TSH is associated with endothelial dysfunction in Metabolic Syndrome: A case control study

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Metabolic Disorders

Background:

• Endothelial dysfunction is a key factor in Metabolic Syndrome (Met S) development.
• Subclinical hypothyroidism (SCH) is increasingly associated with Met S.
• Understanding the link between thyroid function and endothelial health in Met S is crucial.

Purpose of the Study:

• To investigate the association between elevated TSH levels and endothelial dysfunction markers in Met S patients with SCH.
• To compare these markers in Met S patients with SCH versus those without SCH and healthy controls.

Main Methods:

• A study population of 100 individuals (50 Met S cases, 50 healthy controls) was analyzed.
• Met S cases were stratified based on the presence or absence of SCH.
• Serum TSH, nitric oxide (NO), and endothelin-1 (ET-1) levels were measured using validated assays.

Main Results:

• 22 out of 50 Met S cases (44%) had SCH.
• Met S cases exhibited significantly higher TSH and ET-1 levels, and lower NO levels compared to controls (P <0.05 for all).
• TSH positively correlated with ET-1 (r=0.341, P=0.001) and negatively with NO (r=-0.331, P=0.001).

Conclusions:

• Met S patients frequently present with SCH and concurrent endothelial dysfunction.
• Elevated TSH in SCH may drive endothelial dysfunction, contributing to Met S and its comorbidities.
• Screening and treating SCH in Met S patients could mitigate endothelial dysfunction and related health issues.